Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial
- PMID: 25200049
- DOI: 10.1161/CIRCULATIONAHA.113.008227
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial
Abstract
Background: The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown.
Methods and results: In the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) trial, a total of 113 patients were randomized to receive aspirin plus clopidogrel or aspirin plus placebo for 1 year after coronary artery bypass grafting. In this secondary analysis, the 92 patients who underwent preoperative and 1-year postoperative angiograms at 2 centers had each of their coronary stenoses graded serially by using 6 thresholds (grade 0 [0%-24%], grade 1 [25%-37%], grade 2 [38%-62%], grade 3 [63%-82%], grade 4 [83%-98%], and grade 5 [99%-100%]). We compared the incidence and degree of evolving coronary artery disease between the 2 treatment groups. A total of 543 preoperative stenoses and occlusions were quantified and followed. At 1-year postoperatively, there were 103 evolving (94 worsened, 9 improved) and 22 new lesions. The right coronary artery territory and sites proximal to a graft were more commonly associated with worsening coronary artery disease (P≤0.02). There were no differences in clinical events between treatment groups, and the proportion of patients with evolving or new lesions was also similar (70% versus 74%, aspirin-clopidogrel versus aspirin-placebo, respectively; P=0.8). However, in evolving or new lesions, the mean grade change (1.1±1.0 versus 1.6±1.1, respectively; P=0.01) and the proportion of new occlusions (7% versus 22%; P=0.02) were lower in the aspirin-clopidogrel group.
Conclusions: The addition of clopidogrel to aspirin correlates with less worsening of native coronary artery disease 1 year after coronary artery bypass grafting. These findings may help guide post-coronary artery bypass grafting antiplatelet therapy.
Clinical trial registration url: http://www.clinicaltrials.gov. Unique identifier: NCT00228423.
Keywords: clopidogrel; coronary artery disease; platelet aggregation.
© 2014 American Heart Association, Inc.
Similar articles
-
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.Circulation. 2010 Dec 21;122(25):2680-7. doi: 10.1161/CIRCULATIONAHA.110.978007. Epub 2010 Dec 6. Circulation. 2010. PMID: 21135365 Clinical Trial.
-
Eight-year follow-up of the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) trial.J Thorac Cardiovasc Surg. 2018 Jan;155(1):212-222.e2. doi: 10.1016/j.jtcvs.2017.06.039. Epub 2017 Jun 24. J Thorac Cardiovasc Surg. 2018. PMID: 28734623 Clinical Trial.
-
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study.Am Heart J. 2010 Dec;160(6):1178-84. doi: 10.1016/j.ahj.2010.07.035. Am Heart J. 2010. PMID: 21146675 Clinical Trial.
-
Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients.Am J Cardiol. 2009 Jun 15;103(12):1687-93. doi: 10.1016/j.amjcard.2009.02.021. Epub 2009 May 4. Am J Cardiol. 2009. PMID: 19539077 Review.
-
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest. 2004 Sep;126(3 Suppl):513S-548S. doi: 10.1378/chest.126.3_suppl.513S. Chest. 2004. PMID: 15383483 Review.
Cited by
-
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.Cochrane Database Syst Rev. 2017 Dec 14;12(12):CD005158. doi: 10.1002/14651858.CD005158.pub4. Cochrane Database Syst Rev. 2017. PMID: 29240976 Free PMC article.
-
Hospital Variability Drives Inconsistency in Antiplatelet Use After Coronary Bypass.Ann Thorac Surg. 2020 Jul;110(1):13-19. doi: 10.1016/j.athoracsur.2019.12.064. Epub 2020 Feb 11. Ann Thorac Surg. 2020. PMID: 32057813 Free PMC article.
-
Preventive medication efficacy after 1-year follow-up for graft failure in coronary artery bypass surgery patients: Bayesian network meta-analysis.Eur Heart J Open. 2024 Jun 27;4(4):oeae052. doi: 10.1093/ehjopen/oeae052. eCollection 2024 Jul. Eur Heart J Open. 2024. PMID: 38974873 Free PMC article. Review.
-
Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery.J Am Heart Assoc. 2021 Jun;10(11):e020413. doi: 10.1161/JAHA.120.020413. Epub 2021 May 15. J Am Heart Assoc. 2021. PMID: 33998246 Free PMC article.
-
Physiological insights of recent clinical diagnostic and therapeutic technologies for cardiovascular diseases.J Physiol Sci. 2017 Nov;67(6):655-672. doi: 10.1007/s12576-017-0554-8. Epub 2017 Jul 5. J Physiol Sci. 2017. PMID: 28681363 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical